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Background: The Conserved Oligomeric Golgi (COG) complex is involved in the retrograde trafficking of Golgi
components, thereby affecting the localization of Golgi glycosyltransferases. Deficiency of a COG-subunit leads to
defective protein glycosylation, and thus Congenital Disorders of Glycosylation (CDG). Mutations in subunits 1, 4, 5, 6, 7
and 8 have been associated with CDG-II. The first patient with COG5-CDG was recently described (Paesold-Burda et al.
Hum Mol Genet 2009; 18:4350–6). Contrary to most other COG-CDG cases, the patient presented a mild/moderate
phenotype, i.e. moderate psychomotor retardation with language delay, truncal ataxia and slight hypotonia.
Methods: CDG-IIx patients from our database were screened for mutations in COG5. Clinical data were compared.
Brefeldin A treatment of fibroblasts and immunoblotting experiments were performed to support the diagnosis.
Results and conclusion: We identified five new patients with proven COG5 deficiency. We conclude that the clinical
picture is not always as mild as previously described. It rather comprises a broad spectrum with phenotypes ranging from
mild to very severe. Interestingly, on a clinical basis some of the patients present a significant overlap with COG7-CDG,
a finding which can probably be explained by subunit interactions at the protein level.
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Proteins can undergo different forms of post-translational
modification within the endoplasmic reticulum (ER) and
the Golgi. Around 70% of all proteins are glycosylated.
Glycoproteins serve many critical roles in metabolism, in-
cluding protein folding, cell recognition, cell adhesion. . .
The importance of the glycosylation pathway is illustrated
by a group of diseases termed Congenital Disorders of
Glycosylation (CDG). Patients present a broad clinical
spectrum. Usually there is multi-system involvement,
though neurological symptoms and dysmorphic features
often dominate the clinical picture. To date, many types of
CDG involving defects in the biosynthesis, transfer and re-
modelling of the N-glycan have been discovered. Since at
least 200–300 genes are known to be involved in glycosyla-
tion (~1% of the human genome), one expects that the
knowledge of CDG and diagnosis today represents only the
tip of the iceberg. Most types of CDG are caused by muta-
tions in genes directly involved in the glycosylation path-
way, i.e. glycosyltransferases, glycosidases or nucleotide* Correspondence: jaak.jaeken@uzleuven.be
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reproduction in any medium, provided the orsugar transporters. However, a growing number of protein
deficiencies which indirectly affect glycosylation are
reported, for example defects in the Conserved Oligomeric
Golgi (COG) complex [1].
The COG complex consists of eight subunits, orga-
nized in lobe A (COG1 to COG4) and lobe B (COG5 to
COG8). The two lobes are bridged by an interaction be-
tween COG1 and COG8. The complex is involved in
retrograde vesicle transport within the Golgi, thereby
affecting the localization of GEAR proteins (i.e. glycosyl-
transferases, glycosidases, golgin and SNARE proteins).
Correct glycosylation requires that the different proteins
involved are distributed in a defined gradient across the
Golgi cisternae. In patients with COG deficiency the
localization of GEAR proteins is disturbed, leading to
default glycosylation and thus CDG. Interestingly, it
seems that GEAR protein levels are influenced in a dif-
ferent way by defects in lobe A versus lobe B. Until now
it appears that GEARs residing in the early Golgi cister-
nae (e.g. mannosidase II) are more affected when a lobe
A subunit is deficient, while GEARs residing in the late
Golgi cisternae (e.g. galactosyltransferases and sialyl-
transferases) are more influenced by lobe B alterations.
Furthermore, lobe A alterations cause important changesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sylation enzymes in CCD (COG complex-dependent)
vesicles, thereby preventing interaction with their sub-
strate, whereas lobe B deficiency mainly results in
altered steady state levels of these enzymes due to their
translocation to the ER and subsequent proteasomal
degradation [2-7].
Since retrograde trafficking is disturbed in COG defi-
cient cells, a delay in Golgi disruption will be seen upon
treatment of cells with Brefeldin A (BFA). BFA is an in-
hibitor of the GDP/GTP-exchange factor for ADP-
ribosylation factor 1. So, upon treatment coat proteins
will be released from Golgi membranes. This leads to
formation of tubule-like structures and a rapid collapse
of the Golgi into the ER due to retrograde transport.
Using a Golgi protein (e.g. ß1,4 galactosyltransferase 1),
one can visualize its redistribution from the Golgi to the
ER during BFA treatment. A delay in this process will be
seen in COG deficient cells [2].
Mutations in the genes of six different COG-subunits
have been reported, i.e. COG1 and COG4 to COG8 [8-18].
The first patient with COG5-CDG was only recently pub-
lished [12]. The patient presented a mild/moderate pheno-
type, with moderate psychomotor retardation, language
delay, truncal ataxia and slight hypotonia. Here we present
five additional patients with proven COG5 deficiency.
Methods
Glycoprotein analysis
IEF of serum transferrin was performed using the method
described by Carchon et al. [19]. Further delineation of the
glycan structure was obtained by matrix assisted laser de-
sorption/ionization mass spectrometry (MALDI-TOF MS)
of serum transferrin. After PNGase treatment, the released
N-glycans were purified by solid-phase extraction and per-
methylated in the presence of sodium hydroxide. The per-
methylated glycans were analyzed by MALDI-TOF MS in
negative and positive ion mode [20,21].
Molecular analysis
Mutation analysis was performed on genomic DNA for
all patients. Mutation analysis on cDNA was performed
for patients 3 and 4. Total RNA was extracted from
fibroblasts by using the RNeasy Mini Kit (Qiagen, Venlo,
The Netherlands) according to the manufacturer’s proto-
col. To remove residual traces of genomic DNA, the
RNA was treated with DNase I (Qiagen, Venlo, The
Netherlands) while bound to the RNA binding column.
The concentration and purity of the RNA was measured
using a Nanodrop ND-1000 spectrophotometer (Thermo
Scientific, Aalst, Belgium). RNA was reverse transcribed
into cDNA by using the First-strand cDNA Synthesis Kit
(GE Healthcare, Diegem, Belgium) according to the man-
ufacturer’s protocol. In patient 2, 3 and 4 analysis wasperformed through Sanger sequencing (primers available
on demand). Amplification conditions were 2 min at 95°C,
10 cycles of 30s at 95°C, 30s at 65°C (−1°C each cycle),
2 min at 72°C followed by 25 cycles of 30s at 95°C, 30s at
55°C, 4 min at 72°C. Purification of the PCR product was
performed by adding ExoSAP-IT (Isogen, De Meern, The
Netherlands), followed by incubation of the product for
15 min at 37°C and 15 min at 80°C. Sequence analysis was
performed using universal M13 primers (Integrated DNA
Technologies, Leuven, Belgium), Big Dye Terminator V3.1
Kit Cycle Sequencing and 5X Sequencing Buffer (Applied
Biosystems, Gent, Belgium). Sequencing conditions were
3 min at 96°C followed by 25 cycles of 10s at 96°C, 5s at
50°C, 4 min at 60°C. Precipitation of the product was per-
formed with the aid of the Biomek NXp (Beckman Coulter,
Suarlée, Belgium). Mutation analysis was carried out on an
ABI3130xl automated sequence detection system (Applied
Biosystems, Gent, Belgium).
In patients 1.1 and 1.2, the identification of the muta-
tions was performed by whole exome sequencing, using
the Nimblegen Exome Capturing Kit version 2 (Roche,
Vilvoorde, Belgium). Sequencing was performed on the
HiSeq2000 (Illumina, Eindhoven, The Netherlands).
Western blot analysis of the COG5 and COG7 subunits
Control and patients fibroblasts were rinsed twice with
ice cold PBS and lysed on ice for 30 min in lysis buffer
(Ripa: 25 mM Tris pH 7.6, 150 mM NaCl, 1% NP40, 1%
sodium deoxycholate, 0.1% sodium dodecyl sulfate) with
protease inhibitor cocktail (Roche, Vilvoorde, Belgium).
Insoluble material was removed by centrifugation for
30 min at 20,000 g at 4°C. Proteins were quantified using
Micro BCA protein assay kit (Thermo Scientific, Aalst,
Belgium). Equal quantities (15 μg) of protein were mixed
with a reducing LDS loading buffer containing DTT
(Invitrogen). The mixture was incubated 3 min at 100°C.
Proteins were separated on 4–12% Bis-Tris gels (Invitrogen),
and transferred onto a nitrocellulose membrane (GE
Healthcare, Diegem, Belgium). Non-specific binding sites
were blocked by incubating the membrane in TBS con-
taining 0.05% Tween-20 (TBS-T) and 5% non-fat dried
milk for 1 hour at room temperature. The membrane
was then incubated for 1 hour with the primary rabbit
antibody dissolved in blocking buffer. Anti-COG5 and
COG7 antibodies were gifts from D. Ungar (Princeton Uni-
versity, Princeton, USA) and M. Krieger (Massachusetts
Institute of Technology, Cambridge, USA) respectively.
After washing in TBS-T, horseradish peroxidase-linked
secondary goat anti-rabbit antibody (P0448, Dako; used
at a dilution of 1:10.000) was applied to the membrane.
Signals were detected using chemiluminescence reagent
(ECL, PerkinElmer, Zaventem, Belgium) on imaging film
(GE Healthcare, Diegem, Belgium). Signal detection was
performed by autoradiography and quantified with the
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Piscataway, NJ, USA).
BFA treatment of cells
Fibroblasts were grown overnight on glass bottom culture
dishes (MatTek Corporation, Ashland, USA) and trans-
fected with pcDNA3.1 encoding GalT-GFP. Transfected
cells were visualized by confocal microscopy. The BFA
assay was subsequently performed. The medium replaced
by medium containing 5 μg/ml BFA. Time-lapse images
were taken with a Leica Sp5 microscope. A total of 50
images were acquired at the rate of 1/10s (0.3s exposure).




The clinical features of the 6 patients and of the index
patient are summarized in Table 1.
Patient 1.1, patient 1.2 and patient 1.3 are siblings. They
were born in a family of seven children from consanguin-
eous Moroccan parents. Two nephews are known to have
mental retardation of unknown origin.
Patient 1.1 is a 15 year old girl (Figure 1). The preg-
nancy was unremarkable and she was born at term.
General developmental delay and hypotonia was noted
after the age of 1 year, with subsequent delays in fine
motor and language development. At the age of 8 years
she spoke her first words, but she never constructedTable 1 Clinical features of COG5-CDG patients
Index P1.1 P1.2
Ethnic origin Iraqi Moroccan Moroccan
Consanguinity + + +










Microcephaly + + +
Hypotonia + + +
Convulsions - - -
Short stature - + +
Liver involvement - - -
Deafness - - -




Other - - -
NA: not available.sentences. Now, at the age of 15, she communicates with
simplified sign language. Ophthalmologic examination
and hearing tests were normal. Psychological evaluation
could not retain signs of autism. Brain MRI at the age of
10 years revealed a global decrease of white matter and
enlarged lateral ventricles. To date, she presents with
short stature, moderate mental retardation and non-
progressive microcephaly. Slight dysmorphic features are
present, i.e. posteriorly rotated, low set ears, a prominent
nose and low hair line. Menarche occurred at the age of
13. She has genua valga and a wide based gait. Running
is easier for her than walking. Reflexes are brisk.
Patient 1.2 is a 19 year old girl. Birth was complicated
by umbilical cord strangulation. Her global development
was severely delayed, and language development did not
occur. At the age of 6 years she learned to walk inde-
pendently. Ophthalmologic examination and hearing
tests were normal. To date she presents with severe
mental retardation, slight dysmorphism and autistic be-
havior. She can only walk short distances; otherwise the
use of a wheelchair is required. She is unable to dress her-
self or to eat independently. There is urinary incontinence.
Patient 1.3 is a 28 year old woman. She was born at
term. Pregnancy was complicated with premature con-
tractions at 12 weeks gestational age. Developmental
delay was noted at the age of 8 months. She presented
with hypotonia and a delay in motor development. At
the age of 3 she learned to pronounce simple words, but
there was no further language development. She wasP1.3 P2 P3 P4
Moroccan Chinese Italian Belgian
+ - + -
Severe Mild Severe Severe
++ + ++ ++
++ + ++ ++
- - Both -
+ - ++ ++
+ + ++ ++
- - - +
+ - + +
- + + -
- - + +
- - + +
- - + +
- Contractures - Wrinkled
skin
Figure 1 Clinical features of patient 1.1 at the age of 15. Note the short stature (a), strabismus, prominent nose, thin upper lip and
microcephaly (b). Family tree of patients 1.1, 1.2 and 1.3 (c).
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tests were normal. Ophthalmologic examination showed
strabismus due to hyperopia. Brain imaging did not
show any signs of cerebral atrophy. Actually, she pre-
sents with non-progressive microcephaly, severe mental
retardation (IQ < 20) and autistic behavior. She also has
slight dysmorphic features, i.e. low set, posteriorly
rotated ears and a high arched palate. She is dependent
of her environment for daily activities. She is only able
to walk with support. There is urinary incontinence.
Patient 2 is a girl of 9 years old (previously described by
Fung et al. JIMD Reports 2012;3:67–70). She is the second
child of healthy, non-consanguineous parents of Chinese
origin. Pregnancy was complicated by intra-uterine growth
retardation (IUGR). A caesarean section was performed at
the gestational age of 35 weeks due to oligohydramnios. At
the age of 8 months she presented with hypotonia, failure to
thrive, microcephaly, general developmental delay, hepatos-
plenomegaly and flexion contractures of all fingers. There
was no facial dysmorphism. Further investigations revealed
cirrhosis with portal hypertension. No infectious, auto-
immune or metabolic cause of the liver disease was found.
Brain MRI at the age of 13 months showed delayed myelin-
ation. Hearing and ophthalmological tests were normal. A
progressive improvement of developmental milestones oc-
curred. Now she presents with non-progressive microceph-
aly and mild mental retardation (IQ 62).Patient 3 is a 3 year old boy (Figure 2). He is the first child
of consanguineous, Italian parents. During pregnancy IUGR
was noted. He was born at term by caesarean section be-
cause of breech presentation. Body weight and head circum-
ference were at the third percentile, but length was found
far below the third percentile. At 3 months of age, the child
was hospitalized because of important hypotonia, progres-
sive microcephaly, failure to thrive, strabismus, recurrent
urinary tract infections and hepatomegaly. TORCH screen-
ing was negative. Investigations revealed important liver in-
volvement and a neurogenic bladder. Brain MRI at the age
of 1 year showed severe supra- and subtentorial brain atro-
phy (Figure 2). Hearing tests and ophthalmological examin-
ation demonstrated the presence of sensorineural deafness
and cortical blindness respectively. To date the child pre-
sents with severe mental retardation, spastic quadriplegia
and scoliosis. There is no language development. Because of
poor feeding a gastrostomy was performed. Neurogenic
bladder dysfunction was treated with a cystostomy.
Patient 4 is a 3 year old boy (Figure 3). He was born as
the third child of non-consanguineous Belgian parents.
Pregnancy was unsupervised. Vaginal delivery occurred,
despite of breech presentation. He presented with severe
hypotonia and generalized convulsions. Brain MRI at the
age of 5 days was normal. Flexion contractures of knees
and elbows were suggestive for reduced fetal movements.
Clinical examination revealed a dry, scaly skin,
Figure 2 Clinical features and brain MRI of patient 3 at the age of 12 months. Note the important microcephaly, facial hypotonia,
retrognathia and strabismus (a). MRI shows global cerebral and cerebellar atrophy (b).
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the second and fifth finger and a micropenis with crypt-
orchidism. There was slight facial dysmorphism with low
set, posteriorly rotated ears, a prominent nose with a broad
root and retrognathia. The neck was short with loose and
wrinkled skin. Feeding problems due to hypotonia and im-
portant gastroesophageal reflux made tube feeding neces-
sary. Urosepsis at the age of 20 months led to the diagnosis
of neurogenic bladder. Intermittent urinary catheterization
and antibiotic prophylaxis prevented occurrence of further
infections. Hearing tests and ophthalmological examination
showed sensorineural deafness and cortical blindness re-
spectively. The boy now presents with severe hypotonia, fail-
ure to thrive, progressive microcephaly, epilepsy and
profound psychomotor retardation. There is still no head
control. The general condition of the patient gradually
declines.
Glycoprotein analysis
All patients showed a type 2 pattern on IEF of serum trans-
ferrin. MALDI–TOF MS of the N-glycans of serum trans-
ferrin suggested a defect in sialylation and in some of the
patients a milder defect in galactosylation (Figure 4). TheseFigure 3 Clinical features of patient 4 at the age of 3 months. Note th
probably due to reduced fetal movements. The boy presents slight facial d
a prominent nose and thin upper lip.findings were compatible with a deficiency in the late Golgi
glycosylation steps.
Molecular analysis
Whole exome sequencing revealed a homozygous nonsense
mutation in COG5 (c.2518G>T; p.E840X) in patients 1.1
and 1.2. For patient 1.3 mutation analysis was not performed
since no DNA sample was available. Sanger sequencing of
COG5 revealed two different mutations in patient 2
(c.556_560delAGTAAinsCT; p.S186_K187delinsL and c.95T
>G; p.M32R). Patient 3 was found to be compound hetero-
zygous for two other mutations (c.189delG; p.C64Vfs*6 and
c.2338_2340dupATT; p.I780dup). Patient 4 was homozygous
for a missense mutation at the 50 boundary of exon 16
(c.1780G>T; p.V594F), causing a splice of exon 16.
The missense mutation p.M32R affects an amino acid
that is embedded in a conserved region of the protein.
To predict damaging effects of this missense mutation,
the software tool Polyphen2 was used [22]. The missense
mutation was predicted to be probably damaging with a
score of 0.960. The c.556_560delAGTAAinsCT predicts
an in frame deletion. The corresponding amino acid, as
well as the flanking amino acids, are phylogeneticallye overriding sutures, deeply positioned eyes and retrognathia,
ysmorphism with hypertelorism, minor ptosis, posteriorly rotated ears,
Figure 4 Glycan analysis by MALDI-TOF MS. Serum transferrin glycan analysis by MALDI-TOF MS in a control (a) and patients 1.1 (b), 2 (c), 3
(d), 4 (e). All the patients showed a defect in sialylation (*). Patients 1.1 (b), 2 (c) and 3 (d) also showed a slight deficient galactosylation (#).
Symbols: square: N-acetylglucosamine; white circle: mannose; gray circle: galactose; diamond: sialic acid and triangle: fucose.
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in frame insertion. The variant is not present in the
dbSNP Database, or in the 1000 Genomes Project [23,24].
Western blot analysis of the COG5 and COG7 subunits
To examine the impact of the mutations on the stability of
COG5, western blot analysis in control and patients’fibroblasts was performed. A significant decrease in steady
state levels of the COG5 protein was found in our patients
(0 to 25%), as compared to a healthy control. As stable
subcomplex formation between COG5 and COG7 within
lobe B is suggested, stability of the COG7 subunit was also
checked. As expected, steady state levels of the COG7 pro-
tein were significantly reduced (0 to 13%), corresponding
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lian cells (Figure 5). The steady state levels of COG5 and
COG7 correlated with clinical severity.
BFA treatment of cells
To study defects in retrograde trafficking, fibroblasts were
first transfected with GalT-GFP and treated with BFA.
Time lapse videomicroscopy was used to monitor the dis-
appearance of GalT-GFP from the Golgi after the addition
of BFA. A clear delay in the redistribution of the GalT-
GFP into the ER was observed in COG5 deficient cells
compared to control, as shown in Figure 6, after quantifi-
cation of the remaining fluorescence. It has to be noted
that this delay is different according to the observed muta-
tions and suggests a correlation with clinical severity.
Discussion
Most known CDG types are due to defects in genes
involved in either the synthesis of the glycoconjugates, or
of the sugar-donors. COG deficiencies cause CDG ratherFigure 5 Western blot analyses of COG5 and COG7. Western blot analy
steady state levels (b). Note the significant decrease in steady state levels o
control.indirectly by affecting the trafficking and stability of the
glycosylation machinery. Most of the mutations found in
patients are localized in lobe B of the COG complex.
Moreover, some of these mutations lead to complete loss
of the lobe, while complete loss of lobe A has never been
observed in CDG patients. This is consistent with studies
performed in Saccharomyces cerevisiae and Drosophila
melanogaster in which loss of lobe A is incompatible with
life. However, from a clinical point of view most patients
with COG-CDG, irrespective of the subunit affected,
present a severe phenotype. Only a few mild/moderate
cases are described [25].
In 2009 Paesold-Burda et al. published the first patient
with COG5 deficiency. The girl presented only moderate
mental retardation and a moderate delay in language
and motor development with a progressive improvement
in developmental milestones during childhood. We iden-
tified five additional patients with a COG5 deficiency.
Mutation analysis was supported by a significant de-
crease in steady state levels of the COG5 protein onsis of the COG5 and the COG7 protein (a) and quantification of the
f the COG5 and the COG7 protein in the patients compared to
Figure 6 BFA treatment of fibroblasts. Effects of BFA on control and COG5 deficient cells, visualized by time-lapsed video microscopy (a).
Quantification of the remaining fluorescence (b). Note the delay in the redistribution of GalT-GFP from the Golgi into the ER in COG5-deficient
cells compared to control.
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treatment of patients’ cells with BFA. Because recent stud-
ies in mammalian cells indicated that stable subcomplexes
are formed between COG5 and COG7, steady state levels
of the COG7 protein were investigated. A significant de-
crease of the COG7 protein level was detected [26].
Instead of a mild phenotype, we found a spectrum reach-
ing from mild to very severe. Within this broad spectrumsome common characteristics were present, i.e. hypotonia,
microcephaly, some degree of mental retardation, a
marked delay in language development or absence of
speech and a short stature. Most patients showed slight
facial dysmorphism with low set, posteriorly rotated ears, a
relatively short neck with a low posterior hairline and a
prominent nose. Interestingly, patients presenting with
only mild mental retardation (e.g. patient 2) made progress
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while patients on the opposite side of the spectrum, pre-
senting with severe mental retardation, displayed further
clinical deterioration (e.g. patient 4) or exhibited regression
of previously acquired skills (e.g. patient 1.2 and 1.3). Fur-
thermore, clinical features of patients on the severe end of
the spectrum overlap with those of COG7-CDG, except
for neonatal death. For example, patient 4 not only dis-
played loose, wrinkled and dry skin, but also developed
seizures and neurogenic bladder dysfunction. Brain MRI
5 days after birth was normal. However, considering the
progressive microcephaly global cerebral atrophy may be
suspected. The clinical presentation of patient 3 also
shows significant overlap with that of COG7-CDG. The
patient presented with progressive microcephaly and sig-
nificant global brain atrophy on MRI. He also suffered
from significant liver involvement with cholestasis and
neurogenic bladder dysfunction.
In conclusion, patients with COG5-CDG present differ-
ent degrees of clinical severity. Since some of our patients
show a clinical overlap with COG7-CDG, we hypothesize
that interactions at protein level may be reflected in the
phenotype.
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